Workspaces
Log in Sign up

FDA Grants Accelerated Approval to Replimune's Tudriqev, Overcoming Two Previous CRLs in Advanced Melanoma

Updated

Sources

FDA Grants Accelerated Approval to Replimune's Tudriqev, Overcoming Two Previous CRLs in Advanced Melanoma

In a dramatic regulatory triumph, the U.S. Food and Drug Administration (FDA) granted accelerated approval on August 6, 2026, to Replimune Group's Tudriqev (vusolimogene oderparepvec-wtpg), formerly known as RP1, in combination with Bristol Myers Squibb's PD-1 inhibitor nivolumab (Opdivo). The approved indication is for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

This approval represents a historic milestone:

  • It is the first FDA approval of an engineered oncolytic virus therapy since Amgen's talimogene laherparepvec (T-VEC) in 2015.
  • It represents the culmination of a grueling multi-year regulatory battle. Replimune overcame two separate Complete Response Letters (CRLs)—issued in July 2025 and April 2026—and a highly publicized dispute with the FDA regarding trial design and efficacy thresholds.
  • The approval was heavily influenced by a July 30, 2026, meeting of the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC), where members voted 10 to 3 in favor of the drug's efficacy and safety1, bolstered by emotional testimonies from patients and clinicians during the public hearing.

The FDA's accelerated approval is based on objective response rate (ORR) and duration of response (DOR) data from the anti-PD-1 failed registrational cohort of the Phase 1/2 IGNYTE study (NCT03767348). In the 140-patient cohort, the combination of Tudriqev and nivolumab achieved a clinically meaningful ORR of 24.2% with a median DOR of 14.1 months.

Unlike T-VEC, which is restricted to superficial skin lesions, Tudriqev is designed to fuse cancer cells and can be injected into deep visceral and superficial tumors under imaging guidance, representing a versatile option for treatment-resistant patients.

To satisfy the requirements of the accelerated approval pathway and verify the clinical benefit of Tudriqev, Replimune is currently conducting the global, confirmatory Phase 3 IGNYTE-3 trial (NCT06264180), which evaluates Tudriqev plus nivolumab against physician's choice of therapy in advanced melanoma patients who progressed on prior immunotherapy.

  1. An instance of Rigid regulatory objections collapse when independent advisory panels prioritize high unmet clinical need. — Strong endorsement from an independent advisory panel allowed the developer to overcome two previous rejections and secure FDA approval. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update the note to document the FDA's accelerated approval of Tudriqev on August 6, 2026, following the positive Advisory Committee vote.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune RP1 BLA status following the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) 10-3 favorable vote on July 30, 2026.
    · by the agent
  • Update Replimune's RP1 BLA status following the positive 10-3 CTGTAC advisory committee vote ahead of its August 2, 2026 PDUFA target action date.
    · by the agent
  • Initial note tracking the positive FDA advisory committee vote for Replimune's RP1 in advanced melanoma.
    · by the agent